1. The Emerging Roles of the Stress Epigenetic Reader LEDGF/p75 in Cancer Biology and Therapy Resistance: Mechanisms and Targeting Opportunities.
- Author
-
Ortiz-Hernandez, Greisha L., Sanchez-Hernandez, Evelyn S., Ochoa, Pedro T., and Casiano, Carlos A.
- Abstract
Simple Summary: The nuclear protein lens epithelium derived growth factor of 75 kD (LEDGF/p75) has recently attracted considerable attention in the field of cancer research because of its high abundance in cancer cells and its role in promoting tumor aggressive properties. LEDGF/p75 is activated in cancer cells by agents that trigger cellular stress such as chemotherapeutic drugs. This protein has two major structural features, the PWWP domain and the IBD domain. These domains allow LEDGF/p75 to play important roles in cancer cells, including repairing damage to DNA, regulating the processing of messenger RNA, and binding to other nuclear proteins that are necessary to activate cancer-related genes involved in promoting cancer aggressiveness and resistance to therapy. This article discusses LEDGF/p75's role in cancer and therapy resistance, and its potential as a therapeutic target for developing new combinatorial cancer treatments. The lens epithelium derived growth factor of 75 kD (LEDGF/p75) is a transcription co-activator and epigenetic reader that has emerged as a stress oncoprotein in multiple human cancers. Growing evidence indicates that it promotes tumor cell survival against certain therapeutic drugs. The amino (N)-terminal region of LEDGF/p75 contains a PWWP domain that reads methylated histone marks, critical for recognizing transcriptionally active chromatin sites. Its carboxyl (C)-terminus has an integrase binding domain (IBD) that serves as the binding site for the HIV-1 integrase and multiple oncogenic transcription factors. Acting as hubs for protein-protein interactions, both domains facilitate the tethering of oncogenic transcription factors and regulators to active chromatin to regulate mRNA splicing, promote DNA repair, and enhance the expression of stress and cancer-related genes that contribute to tumor cell aggressiveness and chemoresistance. This review summarizes our current knowledge of the emerging roles of LEDGF/p75 in cancer biology and therapy resistance and discusses its potential as a novel oncotherapeutic target in combinatorial treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF